3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Melanoma
25
Hodgkin Disease
20
Lymphoma
9
Skin Neoplasms
4
Neoplasm Metastasis
4
Sarcoma
3
Leiomyosarcoma
3
Neuroblastoma
2
Neoplasms
2
Uveal Melanoma
1
Skin Diseases
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Recurrence
1
Melanoma, Cutaneous Malignant
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Liposarcoma
1
Interventions
Radiotherapy
3
Ifosfamide
2
Doxorubicin
2
indolepropanol phosphate
1
anlotinib
1
Watchful Waiting
1
Tablets
1
Rosuvastatin Calcium
1
Radiotherapy, Conformal
1
Observation
1
Midazolam
1
Filgrastim
1
Digoxin
1
Dacarbazine
1
Chemotherapy, Adjuvant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Sarcoma, Alveolar Soft Part
×
Dacarbazine
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled